Sequencing of Treatments for Patients With Ovarian Cancer
Presented by Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD
Program in Women’s Oncology, Women’s Intimacy and Sexual Health Clinic, The Warren Alpert Medical School of Brown University, Providence, Rhode Island
Presenter’s disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):260–267 |
Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD, discussed the indications for the three PARP agents (olaparib, rucaparib, and niraparib) and strategies for managing PARP inhibitor–related side effects.
For access to the full length article, please sign in